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Abstract
Depression is the preeminent cause of disability internationally. Support-based depression
screening is a nationally recommended means of detecting and treating patients with this
disabling illness. The purpose of the doctor of nursing practice (DNP) practice change project
was to implement an outpatient neurology depression screening protocol so that depressed
patients were identified and received intervention. The project answered whether
implementation of an 8- to 12-week systematic depression screening protocol in a neurology
practice increased the incidence of accurate depression identification and treatment in this patient
population as compared to the 3-month prior baseline. The DNP depression screening project
was based on the salutogenic theoretical framework to emphasize the generation of health
(Becker, Glasscoff, Felts, & Kent, 2015). This generation of health was accomplished through
the preventative intervention of depression screening. The practice change project was based on
an evidence-based practice design using quantitative data collection and measurements. In the
DNP practice change project, N = 66 patients participated in systematic, support-based
depression screening and received treatment recommendations compared to a baseline of 0
systematic depression screening, identification, and treatment. Of the N = 66, 56.1% (n = 37) of
the patients screened positive for depression and 39.4% (n = 26) received treatment if indicated.
Future studies were needed to determine the generalizability of the practice change protocol
methods and results.
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Chapter One: Overview of the Problem of Interest
Depression is the number one cause of disability around the world (World Health
Organization [WHO], 2018). An estimated 300 million people suffer from depression globally
(WHO, 2018). Though effective treatment for depression exists, on average, less than half of
those who are depressed receive treatment (WHO, 2018). Barriers to effective treatment have
included an insufficient number of trained providers, incorrect assessment, misdiagnosis, and
under-diagnosis (WHO, 2018). The purpose of this paper is to describe a doctor of nursing
practice (DNP) practice change project that identified and provided treatment (i.e.,
neuropsychology referral, pharmaceutical prescription, other) if indicated for outpatients with
neurological conditions who screened positive for depression. The purpose of this chapter was to
introduce the background to the practice problem, theoretical framework, purpose, and objectives
of the DNP practice change project.
Background: Definition and Depression
Depression is a mental health disorder with symptoms that may include sadness,
anhedonia, feelings of worthlessness, changes in sleep or hunger, fatigue, and distractibility
(WHO, 2019). Duration of the disorder may be acute or chronic (WHO, 2019). Mild depression
may not require pharmaceutical intervention, but intermediate to severe depression can require
interventions such as talk therapy and medications (WHO, 2019). The effects of depression can
be debilitating, robbing the sufferer of the ability to function normally in his or her everyday life
(WHO, 2019).
Background to the Problem
Chronic comorbidities are often caused by and lead to depression (Bulloch et al., 2015).
Siu and the United States Preventive Service Task Force (USPSTF, 2016) identified depression
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as among the primary causes of disability in persons over the age of 15. The USPSTF
recommended that adults and postpartum women should be screened for depression (Siu &
USPSTF, 2016). Their recommendations advised that screening should be systematic, including
effective diagnosis, treatment, and follow-up (Siu & USPSTF, 2016). USPSTF recommendations
noted that the extent of harm from depression screening was small, while there was moderate
clinical benefit to support-based depression screening (Siu & USPSTF, 2016).
Significance of the Clinical Problem
The disease burden of depression has been internationally recognized (WHO, 2018).
Systematic, support-based, depression screening was recommended to address the problem (Siu
& USPSTF, 2016). Depression is a serious concern in patients with neurological conditions
(Mayberg, 2016). Similarly, persons with mental illnesses have been considered to be at high
risk for depression (Whooley, 2016). The outpatient population of the DNP practice change
project was comprised of diverse patients with various neurological and mental illnesses.
Because of the clinical concern of depression in patients with neurological and mental illnesses,
the systematic, support-based depression screening of neurology outpatients in the DNP practice
change project was significantly important (Mayberg, 2016; Whooley, 2016).
Problem Statement
Although neurology patients are at high risk for depression, the practice at the project site
did not include an evidence-based depression screening and intervention protocol for
identification and treatment of patients.
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Purpose Statement
The purpose of the DNP practice change project was to implement an outpatient
neurology depression screening protocol so that depressed patients were identified and received
treatment recommendations.
Project Purpose
There has been national support for the screening of the general adult United States
(U.S.) population for depression (Siu & USPSTF, 2016). According to practice
recommendations, systematic depression screening included accurate depression diagnosis with
appropriate treatment and follow-up (Siu & USPSTF, 2016). Accordingly, the DNP practice
change project proposed to screen adult neurology patients using a depression screening protocol
that combined screening utilization with subsequent treatment if indicated. The overall goal was
achieved through the approximately 3-month implementation of a system-level depression
screening protocol in an outpatient neurology clinic. One hundred percent of qualifying charts
were reviewed for screening and treatment. Results were analyzed and reported to the
stakeholders.
Project Objectives
The following objectives directed the DNP practice change project:
1. Objective 1: Establish the systematic depression screening baseline among the sample
population.
2. Objective 2: Develop an evidence-based, systematic depression screening protocol at a
neurology center in South Florida.
3. Objective 3: Implement the evidence-based depression screening protocol.
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4. Objective 4: Evaluate the use of the systematic depression screening protocol through
weekly chart audit.
5. Objective 5: Develop a plan of sustainability in the use of the systematic depression
screening protocol at the neurology center in South Florida.
6. Objective 6: Disseminate the findings to the stakeholders.
Theoretical Framework
The USPSTF makes preventive care recommendations for populations that do not have
signs of associated illness (Siu & USPSTF, 2016). In accordance with this USPSTF emphasis on
preventive care regardless of symptoms, the DNP practice change project screened all eligible
patient participants, including asymptomatic patients, for depression. The salutogenic model was
selected as the theoretical framework for the DNP practice change project because the model
emphasizes the generation of health instead of pathogenesis (Becker, Glasscoff, Felts, & Kent,
2015). In their discussion of salutogenesis, Becker et al. (2015) described that problem
elimination was insufficient to produce good health outcomes. Becker et al. (2015) highlighted
the need for building the capacity to attain good health outcomes. Becker et al. s (2015) health
generation philosophy promoted the creation of good health beyond the limitations of a diseasebased model. They endorsed advocacy of a capacity-building model that promoted health,
whether or not disease was actively present (Becker et al., 2015).
Theoretical Framework Constructs
The salutogenic model revolves around the Sense of Coherence (SOC) and General
Resistance Resources (GRR) constructs (Mantas et al., 2015). SOC is characterized by
comprehensibility, manageability, and meaningfulness (Mantas et al., 2015). According to
Antonovsky (as cited in Super, Wagemakers, Picavet, Verkooijen, & Koelen, 2015), the SOC
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and GRR constructs address the individual s sense of confidence based on three concepts: (a)
individuals encounter internal and external environmental stimuli, (b) resources exist to manage
the demands of these stimuli, and (c) the demands of these stimuli are deserving of the
individual s attentive engagement. Antonovsky (as cited in Super et al., 2016) also explained that
GRRs are internal attributes that an individual could use as resources to combat life tension in an
effort towards health maintenance, failure at which leads to health breakdown. Health in this
regard is seen as a continuum between the state of health-ease and dis-ease Antonovsky (as cited
in Super et al., 2015).
Theory Application to the DNP Project
In the DNP practice change project, the salutogenic model influenced project objectives
that consequently improved the neurology clinic s capacity to promote better, depression-related
outcomes for neurology outpatients. Through project implementation, clinicians were educated
about the impact of depression on the health of patients with neurological conditions. Clinicians
were also trained to perform depression screening and understand the importance of treatment
when indicated. Further, the practice change project provided mental health education though
depression screening and treatment interventions to neurology outpatients. The DNP practice
change project, therefore, had the potential to impact the health knowledge and decision-making
of both patients and clinicians in regards to depression and health generation.
Significance of Evidence-Based Practice Project
Depression is a public health concern that is recognized as the most common cause of
disability globally (WHO, 2018). The evidence-based DNP practice change project was
significant because it combatted depression through the creation and implementation of a
depression screening and treatment protocol. Furthermore, the evidence-based DNP practice
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change project was specifically designed to screen for depression in patients with neurological
conditions, a population of particular concern for depression (Mayberg, 2016)
Practice
In their report, Siu and the USPSTF (2016) identified that there was enough evidence to
support the utility of adult depression screening. Walker et al. (2017) enumerated three defining
characteristics of a successful screening program: (a) detection reliability, (b) achieves client
endorsement, and (c) results in effective treatment for clients. These characteristics closely
mirrored the goals of the DNP practice change project. Evaluation of the program also provided
invaluable data regarding population impact and the sustainability of the protocol in neurology
outpatient settings.
Healthcare Outcomes
Although depression is the preeminent cause of disability in the world, it has been
estimated that in some countries, fewer than 10% of sufferers receive treatment for their
depression (WHO, 2018). Among the barriers to effective treatment, such as stigma, was
underdiagnosis of the illness (WHO, 2018). Implementation of successful depression screening
protocols may help reduce the global burden of depression by improving healthcare outcomes
through increased depression detection and intervention.
Healthcare Delivery
No single, universal algorithm for depression screening and treatment was found in the
review of literature for the DNP practice change project. As such, the DNP practice change
project may contribute to the body of literature and worldwide initiatives aimed at addressing
depression and depression screening. Other examples of depression healthcare delivery
programs included the WHO s mental health Gap Action Programme (mhGAP), which provided
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increased access to mental health services and training manuals for lay workers (WHO, 2018).
The DNP practice change project was in alignment with such humanitarian and clinical efforts,
because one of the project s objectives was to improve the preparation of clinicians to effectively
administer depression screening and provide patients with treatment if indicated by their results
(WHO, 2018).
Healthcare Policy
Kellogg, Gainer, Allen, O Sullivan, and Singer (2017) discussed steps to disseminating
innovation at the intraorganizational level. The steps included creating organizational
endorsement, information sharing, peer-peer training, reinforcement, and the process of
scholarship and flexibility (Kellogg et al., 2017). The DNP practice change project used steps
similar to those described by Kellogg et al. (2017) to encourage the neurology clinic to adopt the
depression screening protocol as new organizational healthcare policy.
Summary of Chapter One
Depression is the premier cause of disability around the world, highlighting its public
health importance (WHO, 2108). Siu and the USPSTF (2016) have made significant
recommendations to the medical and U.S. community that systematic depression screening with
supportive services is a beneficial modality for depression identification and treatment in adults.
The DNP practice change project proposed to implement a systematic depression screening
protocol, including screening of adult neurology patients using the Patient Health Questionnaire
9 Item (PHQ-9) screening instrument, clinician training to administer, score, and validate the
PHQ-9, and provision of treatment if indicated.
The salutogenic model of health promotes health generation instead of following a
pathological model (Becker et al., 2015). The support-based, depression screening protocol
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implemented in the DNP practice change project helped patients to maintain or achieve health
through depression screening and score-appropriate intervention (Becker et al., 2015;
Antonovsky, 1987 as cited in Super et al., 2015). The DNP practice change project also
demonstrated potential to impact improvement in depression-related patient outcomes, healthcare
delivery by training clinicians to screen for depression, and the development of depression
screening as organizational policy.
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Chapter Two: Review of the Literature
Depression is a recognized global and national public health problem (WHO, 2018; Siu
& USPSTF, 2016). Effective, systematic depression screening and follow-up care have been
recommended for addressing the crisis (Siu & USPSTF, 2016). The purpose of this review was
to examine the literature regarding the public health concern of depression, the use of systematic
depression screening in outpatient settings, and best practice recommendations for the
implementation of accurate depression screening with appropriate follow-up care among
neurology patients.
Search Engines and Terms
The search engines used in the DNP practice change project were Google Scholar,
CINAHL, and Science Direct. Key search terms and phrases were depression,
screening,

depression prevalence,

Preventive Service Task Force,
salutogenic model,
patients, PHQ-9,

depression

depression screening in outpatient neurology,

salutogenic model,

Aaron Antonovsky,

depression screening and policy reform,
using the PHQ-9,

training depression screening program,

U.S.

applying the

depression in neurology

reliability and validity of the Spanish PHQ-9,
the PHQ-9 and neurology outpatient,

resident

patient health

questionnaire-9, and assessing validity of a depression screening instrument. All Science
Direct queries were between the years of 2014 and 2019. The CINAHL queries depression
screening and policy and patient health questionnaire-9 were between the years of 2014 and
2019. All other CINAHL and Google Scholar searches were between the years of 2014 and
2018.
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Article Review and Selection
Forty-eight articles were reviewed. Fourteen articles in total were selected after abstract
or manuscript review. Twelve articles were selected from original queries. One article, Whooley
(2016), was selected secondarily. Another article, Carey et al. (2014) was selected after
reviewing it as a citation found in Schaeffer and Jolles (2018).
Literature Review Findings: Study Types & Study Summaries
Articles ranging from Level I to Level VII were selected for inclusion in the literature
review. No Level II or Level V articles were used. Findings were discussed according to article
level. Strengths, weaknesses, contradictions, and gaps in the literature were also reviewed.
Level I
The Siu and USPSTF (2016) report was a Level I systematic review. The study
synthesized evidence from various sources in recommendation of depression screening. It was
the only Level I article in this review.
Level III
Carey et al. (2014) conducted a Level III quasi-experimental design study. Their work
compared PHQ-9 screening tool results to providers judgement in the detection of depression.
Sensitivity and specificity of both forms of screening were also compared. Results demonstrated
similar percentages of detection prevalence but widely differing sensitivity and specificity
between the two. This article was the only Level III study in this review.
Level IV
Two articles were Level IV descriptive correlational analyses. Mantas et al. (2015)
performed an observational, transverse, non-experimental, quantitative study (p. 36). Their work
investigated the positive mental health of mental health professionals through the use of the
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Sense of Coherence and Positive Mental Health (PMH) questionnaires. Instrument results were
stratified across diverse variables, including demographic characteristics. The PMH and the
salutogenic Sense of Coherence constructs were the primary, underlying theoretical frameworks
of Mantas et al. s study.
The work of Schaeffer and Jolles (2018) described a cyclical quality improvement
process. Their initiative quantified improvement in depression screening and follow-up of their
population over 90 days. Elements of the process were systematically repeated to document
trends.
Level VI
Two Level VI descriptive studies were included in the review. One was performed by
Walker et al. (2017). In their work, they described their screening implementation program. The
expressed intention of their publication was to elucidate lessons they learned in the process.
These lessons included that prudence is important in deciding how often to screen patients;
screening should be an organized, staffed, procedural process; and clinician engagement in the
screening process is vital to encourage patient participation (Walker et al., 2017).
Bulloch et al. (2015) conducted a cross-sectional descriptive study. The objective of the
study was to determine the prevalence of depression across ten neurological presentations. Their
study results reflected that persons with a history of traumatic brain injury or central nervous
system tumors had the chief point prevalence of depression.
Level VII
The eight remaining articles were editorial or topic authority Level VII works. Whooley
(2016) discussed the 2009 USPSTF recommendations regarding screening for depressed adults.
Whooley (2016) highlighted that the predominant change between the 2009 and 2016 reports is
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the more extensive 2016 discussion of depression in pregnant women. Mayberg s (2016)
editorial, on the other hand, reviewed the 2016 USPSTF recommendation on depression
screening and possible contributions that neurology can make to help innovate depression
screening. The WHO (2018) fact sheet provided an overview of the global problem of depression
across all ages and the need for intervention. Blackwell and McDermott (2014), Beard, Hsu,
Rifkin, Busch, and Bjorgvinsson (2016), and Gelaye et al. (2014) all discussed the PHQ-9 at
length.
Becker et al. (2015) and Super et al. (2015) discussed the salutogenic model of health.
Becker et al. (2015) expertly illustrated how the salutogenic model of health related to concepts
of health promotion, prevention, disease, and other theories (Becker et al., 2015). Super et al.
(2015) described health promotion in the context of patient empowerment and the salutogenic
construct of Sense of Coherence.
Literature Review Synthesis: Significant Findings
A significant finding from this review of the literature was that eight of the 14 articles
promoted depression screening in some way. A ninth article by Super et al. (2015) supported
screening of mental health workers to determine their state of positive mental health, which is
conceptually similar to depression screening. The repeated support in the literature for
depression screening and mental health underscores the importance of the topic of depression
screening. Mantas (2015), Becker et al. (2015), and Super et al. (2015) discussed health
achievement through some context of salutogenesis.
The use of screening tools was another recurring theme in the literature review. Six
articles specifically supported the use of systematic depression screening with follow-up care in
the clinical setting (Siu & USPSTF, 2016; WHO, 2018; Mantas, 2015; Mayberg, 2016; Schaeffer
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& Jolles, 2018; Whooley, 2016). Again, the benefit and importance of screening is related to
depression-associated morbidity and suicidality (WHO, 2018). Three of the six articles supported
using a variation of the PHQ-9 in depression screening (Mantas, 2015; Mayberg, 2016;
Whooley, 2016). Bulloch et al. (2015) used the PHQ-9 to estimate point prevalence data.
According to Bulloch et al. (2015), their work reflected the heavy illness burden of depression in
people with neurological conditions (Bulloch et al., 2015).
The importance and role of mental health clinicians and professionals in depression
screening, interventions, and general mental health recurred in the literature as well (Carey et al.,
2014; Mantas, 2015; Mayberg, 2016; Schaeffer & Jolles, 2018; Siu & USPSTF, 2016; Walker,
2017; WHO, 2018). Four studies

Carey et al. (2014), Schaeffer and Jolles (2018), Siu and the

USPSTF (2016), and Walker (2017)

discussed aspects of training or using techniques to better

engage clinicians and mental health professionals in the process of accurate depression
screening. The WHO (2018) also discussed programs that involved manuals and lay worker
training to improve service access for depressed individuals.
Literature Strengths and Weaknesses
A significant weakness of this literature review was the paucity of articles, other than
Bulloch et al. (2015), directly referring to depression in people with neurological conditions.
Another weakness of the literature reviewed was that each study population was so different. The
variation in study populations made it difficult to generalize study findings to the largely
Hispanic, outpatient neurology population of the DNP practice change project.
Literature Gaps
The literature review also presented gaps about depression and depression screening in
the existing literature. Mayberg (2016) expressed concern regarding whether sufficient resources
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existed to address depression screening needs. Cost and funding for depression may be an
important aspect of future study. Mayberg (2016) also suggested that electrical stimulation to
better understand mood regulation is underutilized.
Schaeffer and Jolles (2018) explicitly identified lack of provider knowledge in
appropriate depression care as a distinct gap in best practice. Their sentiment was echoed
somewhat by Walker et al. (2017) who identified that engaging providers in the depression
screening process can be challenging. WHO (2018) training of lay workers to fill the depression
services gap was a supportive example of Walker et al. s (2017) description of insufficient
clinician engagement in depression care.
Another challenge of best practice in depression screening may be the lack of culturally
diverse screening programs and methods. Of the 14 articles, only Schaeffer and Jolles (2018)
described a program fit for a multicultural system. This was a severe limitation for countries such
as the U.S. that serve diverse populations. Siu and the USPSTF (2016) also noted the need for
more research on the verity of screening tools other than English and Spanish as a practice gap.
Finally, Schaeffer and Jolles (2018) identified that according to Medicaid, although
depression screening was nationally supported, only seven states actually report this important
screening and follow-up information. This stated evidence underscored the importance of
systematic, accurate, effective depression screening with appropriate, subsequent intervention.
No specific universal, standardized, depression screening system was recommended or recurrent
in the literature review. There was a critical paucity of standardized, evidence-based, systematic
depression screening in outpatient, adult neurology in the literature reviewed.
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Summary of Chapter Two
Fourteen sources were explored in the literature review. Authoritative support for
depression screening, training populations and clinicians involved in depression screening, types
of screening tools, identification of challenges to effective screening, and practice gaps were
discussed. Strengths, weaknesses of the review, and contradictions in the literature were also
discussed in the article.
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Chapter Three: Methodology
An estimated 20 million people live with depression in the U.S. (MentalHealth.gov,
2017). Depression occurs more frequently in patients with neurological conditions than in the
overall population (Kanner, 2018). Implementation of standardized depression screening and
evidence-based therapies are crucial, initial actions to improve outcomes for patients who suffer
from depression (Mayberg, 2016). The purpose of the DNP practice change project was to
implement an outpatient neurology depression screening protocol so that depressed patients were
identified and received treatment if indicated. The protocol was implemented in a South Florida
neurology clinic for adult outpatients with neurological conditions. The purpose of this chapter
was to discuss the project design, recruitment process, sample characteristics, and data analysis
plan for the DNP practice change project.
Project Design
The DNP practice change project was an evidence-based protocol that collected
quantitative data. The collection of quantifiable and numerical data for analysis was fundamental
for the evaluation of project outcomes. Important quantitative features of the project design
included patient demographics, counts of completed PHQ-9 questionnaires, PHQ-9 raw scores,
counts of different treatment recommendations, and scores on clinician pre- and post-training
tests. Training and qualifying clinicians to administer the PHQ-9 was another important aspect of
the EBP project design.
Setting
The DNP practice change project was conducted with neurology outpatients during their
doctor s visits at a South Florida neurology clinic. Several steps in the depression screening
process occurred in the examination room, including the consenting of patients to participate,
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PHQ-9 administration and scoring, score validation, and the delivery of treatment if indicated.
The examination room was an appropriate place for depression screening and treatment
recommendations because it was an unmanipulated environment that was customary to patients
examination experience (Gray, Grove, & Sutherland, 2017).
Project Participants
Adult neurology outpatients from a South Florida neurology clinic comprised the patient
sample population of the DNP practice change project. Patients who met inclusion criteria were
recruited to participate in the project, when they arrived for their doctor s appointment, by
convenience sampling methods. Patients demographics varied by race, ethnicity, age, gender,
occupation, and diagnosis. Due to the location of the clinic, a large Hispanic representation in the
patient sample population was anticipated. Clinician participants (medical attendings, medical
residents, medical students, and nursing students) were also recruited by convenience sampling
for protocol training during their rotation days at the neurology clinic. Approximately six to 20
clinicians were initially projected to be involved in the protocol training.
Inclusion and Exclusion Criteria
Patient participants were adults 18 years of age or older, English or Spanish speaking,
and literate or able to comprehend and appropriately answer PHQ-9 questions read to them.
Patient participants also had to pass a pre-screening test (orientation to person, place, and date) to
demonstrate that they were cognitively able to give consent. Patients were invited to provide or
deny consent for their de-identified screening results, demographic information, and diagnosis to
be included in project data reporting and associated publications. Patients who were unable to
voluntarily participate in the depression screening protocol, to consent to allow someone else to
write or verbalize their answers for them, or to give their consent due to neurological, medical, or
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physical limitations were excluded from the project. Submissions from patients who did not
complete the screening process were also excluded from the project.
Recruitment
Rathore et al. (2016) discussed the value and importance of screening for depression in
primary and secondary care settings. Accordingly, the neurology clinic provided an appropriate
setting for participant recruitment and project implementation. Patients were invited to
participate in the DNP project during their routine doctor s visit. Administration and scoring of
the PHQ-9 questionnaire was assimilated into each patient s customary assessment interview.
Sample Participation
Participating patients were introduced to the program during their scheduled neurology
appointments. Patient education about depression was made available in the examination room
for all patients. Those patients who were eligible to participate in the project received a
participant packet, which included an explanation of the project and a statement of
confidentiality. Participants could review the packet while they were waiting to see the doctor in
the examination room. During their assessment interview with the clinician, patients were given
an opportunity to ask questions and give informed consent for voluntary project participation.
PHQ-9 Data Collection Procedures
The PHQ-9 has been used in the diagnostic screening of patients for depression (Beard et
al., 2016; Gelaye et al., 2014). The PHQ-9 questionnaire may be found in Appendix J. The PHQ9 is valid, with strong study reliability, Cronbach s alpha of .89 and .86 (Blackwell &
McDermott, 2014). In using the instrument, patients reported and self-rated the symptoms they
experienced in at least the past 2 consecutive weeks (Blackwell & McDermott, 2014; Moriarty,
Gilbody, McMillan, & Manea, 2015). Patient self-reports totaled to a specific score. That score
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was then interpretable as both a diagnostic and severity measure (Beard et al., 2016;
PHQScreeners & Pfizer, n.d.). A recommended ideal depression detection range on the PHQ-9
was a score

10 (Blackwell & McDermott, 2014). Sufficient specificity and sensitivity to detect

depression using the PHQ-9 could be accomplished by using a baseline detection range of 10 or
greater.
Instrumentation: The PHQ-9 Severity Score and Treatment Algorithm
PHQ-9 scores indicated depression severity and were used to guide recommended
intervention (PHQScreeners & Pfizer, n.d.). Scores

4 received no treatment (PHQScreeners &

Pfizer, n.d.). Scores in the range of 5-9 indicated mild severity and recommendation for followup or close observation (PHQScreeners & Pfizer, n.d.). Scores ranging from 10-14 suggested
moderate depression severity and were accompanied by suggested treatment recommendations
such as counseling, follow-up, or medication intervention for the patient. Scores of intermediate
severity, 15-19, warranted psychotherapy and medication intervention (PHQScreeners & Pfizer,
n.d.). Finally, PHQ-9 depression screening scores ranging from 20-27 indicated that the patient
needed immediate medication intervention and interdisciplinary management or psychotherapy if
they responded poorly to more traditional therapy (PHQScreeners & Pfizer, n.d.). Participant
scores were completed on paper and scanned directly into the electronic medical record (EMR),
where they could later be abstracted and analyzed.
Analyzing the Protocol: Clinician Training Data
Prior to implementation of the PHQ-9 in the patient population, all medical providers
who were involved in the screening and intervention process underwent approximately 20
minutes of training to orient them to the significance of depression screening in the population,
the PHQ-9 instrument, the treatment algorithm, their responsibility to validate screening results,
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and how to correctly document all important information related to the screening (i.e., screening
score, provider validation, treatment recommendations provided according to the PHQ-9
treatment-score algorithm). The training also included a 10-question pre-training and posttraining survey to assess medical provider knowledge acquisition and practice of the protocol.
Careful adherence to the protocol was crucial to maintain the integrity of the study data
generated, collected, and analyzed. This adherence to consistency and standardization of the
administration, algorithm interpretation, and treatment delivery between all medical providers
was integral to the reliability of the evidence-based project results.
The clinician pre-training and post-training survey consisted of 10 questions, including
five knowledge and five attitude questions. The pre- and post-training survey may be found in
Appendix C. The five knowledge questions were based on information providers should be able
to identify regarding the PHQ-9 questionnaire. These questions were validated by two content
experts. The five attitude questions were adapted from the Perinatal Depression (PND) Attitudes
and Screening Acceptability Questionnaire (PASAQ) with permission from the lead researcher,
Dr. Sarira El-Den (El-Den, O Reilly, & Chen, 2018). See Appendix L for the permission letter.
The PASAQ tool was originally created and used to ascertain the attitudes of pharmacists
regarding PND depression screening (El-Den et al., 2018). Five questions from the PASAQ were
selected and adapted to refer to depression and clinicians in language that was more general than
the original pharmacist-focused PASAQ. Clinician participants self-selected one anonymous,
unique, bivariate code, which they supplied on both their pre-training and post-training surveys.
The code would be the same on both surveys, allowing each clinician s pre-training and posttraining survey results to be anonymously linked and compared for changes in clinician
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knowledge or attitude. The bivariate code consisted of the clinician s favorite color and first
three initials of their high school.
PHQ-9 Administration
The PHQ-9 instrument was administered by a qualified medical provider (Blackwell &
McDermott, 2014). Qualified in this context referred to clinician participants who underwent the
protocol training for PHQ-9 administration and scoring. The PHQ-9 was also available in
Spanish (Familiar et al., 2014). For the purposes of the DNP practice change project, the
validated English and Spanish versions of the PHQ-9 were used. This bilingual option minimized
barriers to patients understanding the instrument. After a patient completed the PHQ-9, the score
was validated by the lead neurologist, taking into account relevant patient history and comorbid
conditions (Blackwell & McDermott, 2014; Corson, Gerrity, Dobscha, 2004 as cited in
Blackwell & McDermott, 2014).
PHQ-9 and Data Collection
The patient population of the South Florida neurology clinic was diverse. A large subset
of Hispanic patients understood, spoke, and read fluent English, Spanish, or both. The PHQ-9
was implemented in a variety of ethnologically and racially diverse primary care, patient
populations (Gelaye et al., 2014). This diverse application of the PHQ-9 made it an appropriate
screening tool for the socio-ethnically diverse patient sample of the DNP practice change project.
These diverse dynamics also provided an opportunity to collect demographic-rich data. Data
collected in the DNP practice change project was analyzed using Statistical Package for Social
Sciences (SPSS) software and other appropriate modalities as needed.
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Descriptive Data Analysis
Descriptive data analysis in the DNP practice change project provided information to
better understand the characteristics of the sample population and their depression screening
results. Due to small participant sample sizes and incomplete clinician training data, inferential
statistics could not be provided. Descriptive statistics, such as incidence, were discussed.
Nominal and Demographic Data
The demographic characteristics initially selected for analysis were patient occupations,
age, ethnicities, race, gender, and neurological diagnoses. Patient occupation categories included
medical, engineering, trade work, labor law enforcement, retired, student, disabled, and other.
Race was defined as White, Black/African American, American Indian, Alaska Native, Asian,
and Native Hawaiian/Pacific Islander (United States Census Bureau, 2017). Ethnicity primarily
included Hispanic and Not-Hispanic (United States Census Bureau, 2017). Hispanic consisted of
Puerto Rican, Cuban, Cuban-American, and other Hispanic. Neurological diagnoses were
indicated by International Classification of Disease, Tenth Revision (ICD-10) codes.
Descriptive and Inferential Statistics
Counts and percentages of the sample population were categorized by age, gender, race,
ethnicity, occupation, and primary ICD-10 neurological diagnosis. Percentages and counts of the
PHQ-9 depression raw scores, score ranges, functional difficulty, and treatment
recommendations results were also stratified by age, gender, race, ethnicity, and primary ICD-10
neurological diagnosis. Due to small sample size, inferential statistics were not applicable to the
DNP practice change project, but incidences were utilized and reported. Patient counts according
to each of the following was collected: raw score number, demographic category, self-reported
score range, self-reported level of functional difficulty, and type of treatment recommendation
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category was collected. These collected counts were organized in Excel and SPSS. Then the
counts were analyzed in SPSS for descriptive statistics, such as incidence and percentage.
Bivariate descriptive analyses comparing each category of patient demographics (i.e., race, age,
gender) to raw PHQ-9 depression score, score range, treatment recommendations, or functional
difficulty were then performed in SPSS.
Paired t-Test
The number of clinician participants who completed the training was also quantified.
Collection of linkable pre-training and post-training test results was planned but not possible due
to incomplete data. Paired t-test analysis would have been used to evaluate the five knowledge
questions. The goal of comparing clinician pre-training and post-training tests was to determine
if clinician knowledge and attitudes regarding screening patients with neurological conditions for
depression and the PHQ-9 instrument changed after training and protocol participation.
Data Management and Storage
Patient Health Questionnaire-9 item scores along with related descriptive data were
collected and stored. Due to incomplete pre-training and post-training test results, inferential data
was not possible. Data from the provider pre-and-post-training test results were incomplete, but
recorded and stored. Completed paper PHQ-9 questionnaires were scanned immediately into the
EMR. See the consent form as Appendix F.
Data Collection Time Frames
Data collection occurred in several time frames. Each PHQ-9 survey could take
approximately 5 minutes for patient completion (Blackwell & McDermott, 2014). The amount of
time provided for each patient to complete their PHQ-9 was adjusted to accommodate patient
test-taking needs. Validation of PHQ-9 results by the lead neurologist discretionarily have taken
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a minimum of a few minutes upwards to approximately 1 hour. PHQ-9 administration occurred
during doctor visits with the lead neurologist on days when appointments were available in the
neurology clinic. The entire implementation and collection process took place over an
approximately 3-month period from May 2019 through August 2019.
Ethical Considerations
Best practice for adult depression screening includes support systems for accurate
identification and treatment of depression (Siu & United States Preventive Service Task Force
[USPSTF], 2016). Prudent clinical care should also reflect ethical decision making (Hsin &
Torous, 2016). Depression screening best practice should also be ethical. The ethical
considerations related to the DNP practice change project included principles of ethics, issues of
consent, scientific benefit, and security measures for study participants and data collection.
Health Insurance Portability and Accountability Act of 1996
The Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule
was adhered to in the DNP practice change project. HIPAA accountability was particularly
important in regards to the use of the EMR in the practice change project. The HIPAA Privacy
Rule outlined the stipulations by which protected health information may be utilized or disclosed
for studies (U.S. Department of Health & Human Services [HHS], 2018. Regarding research,
HIPAA ensured that researchers have access to needed study data while protecting identifiable
patient information (HHS, 2018). HIPAA law also specified precisely which data items must be
removed from protected health information to ensure that utilized information was de-identified
and unlinkable to the individual source (Polit & Beck, 2017). Full adherence to the Privacy Rule
was expected of all clinicians and staff involved in the project at all times.
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Confidentiality and Consent
Practicing patient confidentiality is a demonstration of respect for a patient s autonomy
and their trust in their provider s discretion (Saunders, 2016). Anonymity and disclosure were
also aspects of confidentiality (Saunders, 2016). For instance, confidentiality assumes patient
awareness that sharing on their part is an expectation congruent with their role as a participant in
their own healthcare (Saunders, 2016).
Medical literature recommended attainment of patient consent regardless of anonymity
(Saunders, 2016). In the DNP practice change project, patients were provided with an
explanation of the program and an invitation to participate in the depression screening protocol.
Patient participants also had the right to informed consent to their participation in the depression
screening process, data collection, and data publication. Informed consent implies a process in
which the patient is informed regarding their health condition and treatment options as part of an
ongoing dialogue between the provider and the client (Farmer & Lundy, 2017). Anonymity and
publication of de-identified data was guaranteed in the patient consent process. The consent form
can be found as Appendix F of this manuscript. Participating clinicians also received an
opportunity to be informed about the depression screening protocol, their role in it, and their
right to voluntary consent to participate in the screening process and permit the publication of
their de-identified pre-training and post-training test results.
Beneficence
Beneficence reflects the benefit-harm ratio in EBP and research (Hofmann & Stanak,
2018). Beneficence represents the delicate balance between maximizing benefits to patients,
while minimizing the risks associated with those same benefits (Bonney, 2014). Beneficence is
also a part of informed consent (Roberts & Kim, 2018). It is the responsibility of researchers to
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make sure that patients feel that their participation in a study is of their own free will (Roberts &
Kim, 2018). Coercion works opposite to this goal of patient freedom, including freedom from
harm and freedom to participate (Roberts & Kim, 2018). Beneficence was demonstrated in the
DNP practice change project because patients who were identified as depressed were given the
benefit of treatment recommendations, at little risk of harm to themselves or participants who
screened negative for depression.
Fidelity and Non-Maleficence
Fidelity indicates how closely project implementation follows the intended
implementation design (CDC, 2018). Non-maleficence reassures patients that they will not be
harmed in the process of receiving care or during an intervention (Bonney, 2014). The DNP
practice change project did not include any component that could physically harm patients in the
process of completing the PHQ-9. Regarding fidelity, careful adherence to the project design and
protocol process was imperative for participant safety and project continuity. Provider validation
and correct utilization of the score-related treatment algorithm minimized the risk of incorrect
diagnosis and potentially harmful results for patients.
Data Storage and Data Security
PHQ-9 instruments, results, and demographic data were securely stored in the medical
record. Completed paper PHQ-9s was scanned into the EMR for reference and retrieval. The
DNP student or the clinician evaluating the patient also manually input the PHQ-9 data into the
patient s EMR visit report. To protect patient confidentiality and the integrity of the data,
modification of the data was restricted in access to clinic staff only. Statistical analysis of the
data was conducted and stored on the DNP student s password-protected computer. This
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information was also backed up on a locked universal serial bus (USB) flash drive that remained
in the possession of the DNP student.
Scientific Benefits
The DNP practice change project could also be considered an evidence-based quality
improvement (EBQI) initiative. EBQI is defined as a methodical, multi-faceted implementation
approach that links scientific discovery and clinical EBP through the collaboration of
researchers, leaders, and clinicians (Goldstein et al., 2018). Through depression screening, this
practice change project applied EBP and interprofessional collaboration to improve health
outcomes for neurology outpatients in a South Florida outpatient neurology clinic.
Expected Outcomes
The ultimate goal of the DNP practice change project was to implement a depression
screening protocol for outpatients with neurological conditions in a South Florida neurology
clinic. Duration of the practice change project was approximately 3 months. Success of the
practice change project was measured by depression identification and treatment
recommendation for at least one patient.
The objectives and corresponding expected outcome measures of the DNP practice
change project were as depicted in Table 1.

Table 1
Summary of Objectives and Outcomes
Objective

Outcome

Objective 1: Establish the depression
screening baseline among the sample
population.

Documentation of the systematic depression
screening baseline
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Objective 2: Develop an evidence-based,
systematic depression screening protocol at a
neurology center in South Florida.

Creation of a support-based protocol that
consists of screening tool utilization, clinician
validation of tool results, provision of scorespecific intervention, and provider training on
the overall process (Siu & USPTF, 2016)

Objective 3: Implement the evidence-based
depression screening protocol.

Success of the practice change pilot will be
measured by completion counts of PHQ-9
screening in the sample population as well as
provider pre- and post-tests.

Objective 4: Evaluate the use of the
systematic depression screening protocol
through weekly chart audit.

A spreadsheet will be used to organize and
reflect the weekly counts of sample
population depression screening as well as
new provider trainings and pre-tests or
existing provider post-tests

Objective 5: Develop a plan of sustainability
in the use of the systematic depression
screening protocol at the neurology center in
South Florida.

The sustainability plan will include an
estimated annual budget, equipment needed
to continue the program, EMR updates or
programming that must be maintained,
training tools and a clear training program,
and provider buy-in

Objective 6: Disseminate the findings to the
stakeholders.

A program analysis including counts of
depression screening, interventions,
comparative analytics of the sample
population scores and demographics,
statistical analysis of the provider training per
the pre and post test results as training
efficacy measure, budget data, and
unexpected findings was supplied to the
stakeholders.
Note. Side-by-side list of each objective and corresponding expected outcome.
Timeline of Project Phases
Step one was to determine whether support-based, systematic depression screening
including the utilization of a screening tool was occurring at the neurology clinic. A needs
assessment was completed. The needs assessment demonstrated that no systematic evaluation
and screening tool was being used in the neurology clinic s practice to identify and treat
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depression according to national best-practice recommendations. A baseline was established of 0
system-wide, support-based, routine depression screening of all neurology outpatients at the
neurology clinic. This step was completed by August 28, 2018.
The second step in the process was to develop an overview of the protocol and its
purpose. The protocol proposed to preventatively screen all eligible patients for depression in an
effort to maximize health in the neurology patient population. Clinician participants used a
standardized depression screening tool, the PHQ-9, to identify depression and inform treatment if
indicated (i.e., referral, treatment, or follow-up) in consenting, adult, neurology patients. The
selected depression detection and screening instrument was the PHQ-9. Patients were only
screened once during the protocol implementation. The overall project plan was presented to
primary stakeholders for approval and feedback. The protocol development process took place
over approximately 8-16 weeks and was completed by January 28, 2019.
Obtaining organizational approval from the neurology clinic s operating manager for the
implementation of the depression screening protocol in a representative sample of the neurology
outpatients was the third step. Specifically, protocol implementation in a sample of the lead
neurologist s patient population was requested. Approval was secured from the inception of
concept development for the project and was achieved by August 28, 2018.
In the fourth step, IRB approval was obtained to implement the DNP practice change
project. IRB approval took approximately 4 weeks. Approval was secured before May 6, 2019.
The fifth step, protocol implementation, was conducted from May 6, 2019 to August 1,
2019. The training program for the residents, medical students, and lead provider was conducted
first. The provider training consisted of (a) a depression screening pre-training survey, (b)
provider education to review current statistics and severity of depression in the general
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population and in neurology in particular, (c) review of national recommendation for
standardized depression screening and follow-up in the general population, (d) introduction to
the screening instrument and administration best practice, and (e) step-by-step demonstration and
explanation of how providers would use the screening tool and report results in the medical
record.
According to clinic practice, residents and medical students initiated patient assessment
interviews. Next, the lead neurologist continued each patient examination. A first line of defense
for success of the DNP practice change project was educating clinicians about the depression
screening procedures and securing their adherence to the protocol. Collaboration with the
residents coordinator on protocol development was important to facilitate the education and
training of the residents and students. Key teaching points, group learning styles, the most
effective way to teach the residents and students, and securing the time to teach the residents and
students were discussed with the resident coordinator. The DNP student used insights from these
discussions in the creation of the depression screening training for clinician participants.
The key facets of the clinician depression screening training included approximately 20
minutes of interactive introduction to the protocol, relevance of depression screening, and
completion of a sample screening. Training of a single group of clinician participants took up to
a day, including guiding the clinician participants through their day of depression screening.
Otherwise, training was variable and repeated throughout the protocol implementation process
according to incoming student and resident clinician schedules.
During the patient depression screening process, patients were first brought into the
examination room for their scheduled doctor s visit. They were introduced to the opportunity to
be screened for depression as part of the project by a clinician. Patients who were willing to
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participate were pre-screened for participation appropriateness by the clinician, assessing the
patient for alertness to person, place, and date (month and year minimum). The clinician then
gave a participation packet to patients who passed the pre-screening. Information about the
project, how patients information would be used, confidentiality, how to complete the PHQ-9,
the demographic survey, and next steps were explained to patients. Patients self-reported their
symptoms in the PHQ-9. Then, the clinician collected the PHQ-9, tallied the score, and reported
the score to the lead neurologist. The lead neurologist validated the score and gave treatment if
indicated. The DNP student input a summary of the PHQ-9 results and corresponding treatment
if indicated into the patient s visit record in the EMR.
The sixth step was to evaluate selected EMR charts for documentation the completed
PHQ-9, PHQ-9 results, and treatment if indicated. PHQ-9 data from each screening was
electronically recorded into the EMR for documentation, storage, and study retrieval. Screening
incidences were recorded for later comparison. Collection of all the data was completed by
August 1, 2019.
Step seven was to evaluate the protocol data results and project implementation overall.
All patient participants PHQ-9 and treatment recommendation results were collected for
analysis. Clinician participant pre- and post-training data were also collected for analysis as well
as for user feedback. Analysis of the data was completed by November 1, 2019.
The eighth step included sustainability recommendations based on the depression
screening implementation and data results provided to the operating manager. Stakeholders were
provided with a comprehensive summary of the data results and operational costs of the protocol
implementation. This step was completed by December 6, 2019.
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Participation Time
Clinician participants received specific protocol training as part of the standardization of
the depression screening process at the neurology center. Their training was aimed at assuring
provider understanding of the PHQ-9 questionnaire and how to use it, current depression
screening best practice, and appropriate, score-specific follow-up actions to be used in the
validation process. Because residents rotate through the center, the training was conducted per
rotation and on an individual basis as needed. The initial 20-minute orientation to the protocol
was extended up to 1 hour to accommodate training questions and answers if needed. Training
culminated in individual clinician participation in the protocol for the duration of their clinical
rotation. Patients were screened with the PHQ-9 depression screening test once during protocol
implementation.
Other aspects of the DNP practice change project also required time. The DNP student
needed 1 week of collaborative effort with the operating manager of the clinic to confirm goals
and permission for systematic implementation of the protocol at the practice site. Final
Institutional Review Board approval took approximately 4 weeks. In terms of resident
participation, it took at least a week to confirm important aspects of the interactive resident
training program with the resident coordinator. Then, it took up to 4 weeks to create the resident
training program.
Technical and logistical time considerations included establishing the baseline for
systematic depression screening at the neurology clinic 3-4 months prior to protocol
implementation. The interactive resident training took approximately 20-60 minutes for each
resident or group of residents to complete. Then, the training required repetition over several
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days depending on residents schedules, the arrival of new residents, or unforeseen time
conflicts.
Implementation time was another consideration. Completion off the PHQ-9 instrument
itself took between 5-15 minutes to complete. Five minutes was a completion time indicated by
Blackwell and McDermott (2014). Clinician scoring of completed PHQ-9s took approximately 5
minutes. PHQ-9 score validation and treatment recommendations from the lead neurologist could
take between 30 minutes to an hour. The evaluation, interpretation, and reporting of project data
took months to complete after protocol implementation was complete.
Resources and Budget
The DNP practice change project required technological and human resources. The
neurology clinic s EMR system, Vertex, was used for storing the PHQ-9 screening results, and
provider documentation of PHQ-9 validation and treatment recommendations. Paper PHQ-9s
were scanned into Vertex. PHQ-9 results were also charted in Vertex. As Vertex was established
at the neurology clinic, there was no additional charge for the use of Vertex. The EMR builder
and providers involved in the screening earned no additional payment for their participation in
the depression screening protocol. The DNP student continued to travel to South Florida from
Texas, requiring a monetary investment of approximately $2000 for air travel and an estimated
$1000 for car travel. Paper PHQ-9 questionnaires were printed at no extra charge to the
organization. Costs of professional statistical analysis of project data was estimated at $500.
Minimal project costs included printing and paper at an estimated 10 cents a page at 100 pages,
$10 during the protocol implementation. Table 2 is a summary of the estimated project costs.
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Table 2
Project Budget
Item
PHQ-9 printing
DNP student s air travel
DNP student s car travel
Statistician fees
Note. Estimated project expenses.

Cost
$.10 x100 copies= $10
$2000.000
$1000.00
$500.00

Sustainability
An estimated yearly budget, equipment for program continuation, EMR software and
systemic maintenance and updating as needed, a clear training program with appropriate training
tools, and provider endorsement were all needed to support protocol sustainability. The careful
organization of PHQ-9 data collection and storage was another key to sustainability. Managing
the PHQ-9 administration and documentation entailed ensuring that the data was saved and the
PHQ-9 was preserved for continued future retrieval as part of the medical record.
The clinician training portion of the protocol was another essential aspect of
sustainability. Successful project implementation and sustainability relied heavily upon the
participation of the resident program coordinator. Resident and student clinicians rotated through
the neurology clinic after weeks or months of training, sometimes returning for another clinical
rotation at the neurology clinic. The resident program coordinator oversaw all training and
rotations. The coordinator provided a source of continuity regarding what and how the residents
learned and practiced while they are in the neurology center. Collaboration with the resident
coordinator was essential to create a standardized, repeatable depression screening program for
the residents, students, and other clinicians. In regards to sustainability, the resident program
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coordinator would be responsible for the continued training and oversight of the depression
screening protocol among the clinicians.
The Risk-Benefit Ratio
Risk is inherent in all research (Polit & Beck, 2017). Minimal risk is no more extreme
than the risk experienced in daily living or ordinary procedures (Polit & Beck, 2017). Risk posed
to study participants that is more than minimal should be mitigated as much as possible (Polit &
Beck, 2017). When the anticipated risk outweighs study benefits to participants, then the study
should be reformatted altogether (Polit & Beck, 2017). The risk-benefit ratio should account for
whether or not the risk posed to study participants is proportionate to the study s benefit to
society (Polit & Beck, 2017). Ultimately, the potential risk posed to study participants should not
outweigh the humanitarian profit of the possible knowledge obtained by the study (Polit & Beck,
2017).
Through their research, Siu and the USPSTF (2016) identified that depression screening
has minimal risk of adverse effects to participants. Thus, the human subjects in the DNP practice
change project were at little risk of harm from the screening itself. Siu and USPSTF (2016)
research indicated incidents of age-related gastrointestinal bleeding in reaction to SSRIs but still
concluded that the net benefit of screening outweighed this potential harm. In the DNP practice
change project, patients were given the benefit to discover if they were living with depression
and to receive intervention to improve their condition.
Risk Minimization Plan
Morrato and Smith (2015) highlighted the importance of recognizing that risk
minimization was an opportunity for pharmaceutical companies to increase trust between
clinicians and patients. Similarly, in the DNP practice change project, anticipating and planning
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for risk was a matter of stewardship and honoring participant trust. Potential risks to patients
included unintended emotional response triggered by the screening process, incorrect patient
translation or interpretation of the PHQ-9 questions, and missed or incorrect depression
diagnosis.
During protocol implementation, each patient was already assigned a qualified physician
as part of the routine assessment interview. This clinician was available to support and assess the
patient if they experienced an unintended emotional response to any part of the depression
screening process. The DNP student, a certified psychiatric-mental health nurse, was also
available to support each participant.
In the event of a Spanish-English language barrier, a physician or member of the staff
was always available to communicate with patients in Spanish and to assist them in
understanding and completing the PHQ-9 correctly. Available medical providers who could
communicate in Spanish included the DNP student and the lead neurologist. The valid, reliable
Spanish version of the PHQ-9 was provided for Spanish-speaking patients who could not read
and understand English (Zhong, Gelaye, Fann, Sanchez, & Williams, 2014). Depression
screening was limited to English and Spanish because providers who spoke other languages were
not always available to assist patients with PHQ-9 interpretation and completion.
Missed or incorrect diagnosis of depression in a participant was grounds for readministration and re-validation of the patient s PHQ-9. Participants in such a scenario would
have been provided an explanation of their revised results and the opportunity to ask the clinician
questions about their repeat screening.
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Summary of Chapter Three
The DNP practice change project design demonstrated the application of quantitative data
collection methods to EBP. Through the use of the methods such as the PHQ-9 administration
and clinician training described in this paper, depression can be detected, classified by severity,
and treated, with patient outcomes ultimately improved (Beard et al., 2016; Mayberg, 2016;
PHQScreeners & Pfizer, n.d.). In the DNP practice change project, a standardized screening
protocol was implemented and provided resulting participant data. Practical keys to project
sustainability included standardization and preservation of protocol guidelines and PHQ-9
administration.
The DNP practice change project was also an opportunity to improve depression
identification and treatment if indicated for patients with neurological conditions. Important
ethical considerations of the project included confidentiality, consent, beneficence, fidelity, nonmaleficence, and the safety of participants and their data. Careful adherence to protocol and
ethical best practice in this DNP practice change project protected the voluntary sample
participation, reliability and security of the data, and efficacious patient and project outcomes.
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Chapter Four: Project Evaluation
According to the WHO (2018), depression is the foremost cause of disability around the
world. The support-based, systematic screening of adults for depression is nationally
recommended (Siu & the United States Preventive Services Task Force [USPSTF], 2016).
Moreover, depression is a concerning comorbid disability in patients with neurological
conditions (Mayberg, 2016). The DNP evidence-based project discussed in this chapter was the
implementation of a depression screening protocol for outpatients with neurological conditions.
The Patient Health Questionnaire 9-item (PHQ-9) screening tool was utilized in the screening
process. The purpose of this chapter is to discuss the results, significant findings, strengths,
limitations, implications of the DNP essentials, and conclusions of the DNP practice change
project.
Results
The DNP practice change project implementation process included several steps. Patients
with neurological conditions and clinician participants, referring to medical residents, neurology
attendings, and medical and nursing students, were recruited. After clinician participants were
trained to screen patients for depression, they administered and scored patients self-reported
PHQ-9 tests. The lead neurologist validated PHQ-9 results and made treatment recommendations
as necessary. Discussion of the results in this chapter included description of project findings,
strengths, limitations, recommendations for stakeholders, and future considerations.
Participant Demographics
The sample patient population of the DNP practice change project consisted of N = 66
patients with neurological conditions. As shown in Table 3, the patient sample consisted of male
and female adults in age ranges from 18 to 60 and older, representing seven ethnicities, five
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racial categories, and comorbid or primary neurological diagnoses. There were 53% (n = 35)
males and 47% (n = 31) females. By ethnicity, 36.4% (n = 24) were Non-Hispanic, 40.9% (n =
27) Hispanic, 3.01% (n = 2) other, and 19.7% (n = 13) not indicated. See Table 4 for ethnicity
details. Categorized by race, 39.4% (n = 26) of participants were White, 22.7% (n = 15) Black,
10.6% (n = 7) multiple races, 12.1% (n = 8) other, and 15.2% (n = 10) not indicated.
Diagnostically, 90.9% (n = 60) of patients had comorbid neurological conditions, 7.5% (n = 5)
had primary neurological diagnoses, and 1.5% (n = 1) was not indicated.
Table 3
Summary of Sample Demographics
Category
Gender

N = 66

(100%)

Male
Female

35
31

53
47

18-20
21-29
30-39
40-49
50-59
60+

1
2
6
11
22
24

1.5
3
9.1
16.7
33.3
36.4

Non-Hispanic
Hispanic
Other
Not Indicated

24
27
2
13

36.4
40.9
3.01
19.7

White
Black
Multiple
Other
Not Indicated

26
15
7
8
10

39.4
22.7
10.6
12.1
15.2

Neurological Comorbidities

60

90.9

Primary Neurological

5

7.5

Age

Ethnicity

Race

Diagnosis

40

Diagnosis
Not Indicated

1

1.5

Note. The Puerto Rican, Cuban, Cuban-American, and other Hispanic ethnicities were
combined under the ethnicity category entitled Hispanic.
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Table 4
Counts and Percentages of Patient Ethnicities
Category
Non-Hispanic
Hispanic

N = 66
24
27
N = 27
5
7
3
12

Puerto Rican
Cuban
Cuban-American
Other Hispanic
Left blank
Other

(100%)
36.4
40.9
(40.9%)
7.6
10.6
4.5
18.2

13
2

19.7
3.0

Note. The Puerto-Rican, Cuban, Cuban-American, and other Hispanic
categories are enumerated in this chart as subcategories under Hispanic.
Expected Outcomes
The purpose of the depression screening protocol was to identify and treat if indicated
depression in patients with neurological conditions. The project had six expected outcomes.
These six expected project outcomes aligned with the overall project purpose.
The first outcome was the documentation of the systematic depression screening baseline.
Next was the creation of a support-based protocol that consisted of screening tool utilization,
clinician validation of tool results, provision of score-specific treatment recommendations, and
clinician training on the overall process (Siu & USPTF, 2016). The third outcome was the
successful implementation of the practice change protocol as quantified by the number of
completed PHQ-9 screenings and clinician pre-training and post-training tests. The following
outcome was the use of a spreadsheet to organize and reflect the number of PHQ-9 screenings
and clinician pre-and post-training tests completed each week. Fifth was the provision of a
sustainability plan, including the estimated annual budget, equipment needed to continue the
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protocol, EMR updates or programming that must be maintained, training tools with a clear
training program, and provider endorsement. The sixth outcome was the submission of protocol
implementation data to the stakeholders, including descriptive statistics of screening results,
sample demographics, clinician training efficacy, budget, and unexpected findings.
Evaluation of Outcomes
The DNP practice change project was directed by six objectives. The first objective was
to establish the depression screening baseline among the sample population. Next was to develop
an evidence-based, systematic depression screening protocol at a neurology clinic in South
Florida. Third was to implement the evidence-based depression screening protocol. The fourth
outcome was to evaluate the use of the systematic depression screening protocol through weekly
chart audit. After that, the objective was to develop a plan of sustainability to continue the
systematic depression screening protocol at the neurology clinic in South Florida. The final
outcome was to disseminate project findings to the stakeholders. Table 5 is a summary of the
objectives, outcomes, and evaluation of outcomes.
Objective 1: Establish the depression screening baseline among the sample population.
A needs assessment was conducted prior to protocol implementation. The needs
assessment identified that no systematic, support-based depression screening protocol was being
routinely utilized in the management of all patients with neurological conditions. The baseline
count for systematic, support-based depression screening was 0.
Objective 2: Develop an evidence-based, systematic depression screening protocol at a
neurology clinic in South Florida.
A systematic, support-based depression screening protocol for outpatients with
neurological conditions was created based on evidence-based best practice recommendations by
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Siu and the USPSTF (2016). The protocol was tailored to the unique needs of the South Florida
neurology clinic. Components of the protocol included consenting all participants, training
clinicians to screen patients for depression, administration of the PHQ-9 to patients, and PHQ-9
score validation and treatment if indicated by the lead neurologist.
Objective 3: Implement the evidence-based depression screening protocol.
Sixty-six patient participants consented, were pre-screened, and completed PHQ-9 tests.
Clinician participants were trained to administer and score the PHQ-9 screening test. Patient
participants were pre-screened for alertness and orientation. The depression screening process
was explained to patients who passed the pre-screening test and signed their consent to
participate in the project. Patient participants received a participant packet that contained an
explanation of the protocol, a consent signature page, the national suicide prevention hotline
number, a demographics survey, and the PHQ-9 test. PHQ-9 tests were scored by a clinician and
validated by the lead neurologist. The lead neurologist provided treatment recommendations as
needed to patients who tested positive for depression. All survey data was collected, reviewed,
and recorded in the EMR. The practice change project took place from May to August 2019.
Objective 4: Evaluate the use of the systematic depression screening protocol through
weekly chart audit.
Every phase of the implementation process was managed and reviewed daily by the DNP
student. All screening exams were securely stored daily. Patient screening data was
intermittently input into the EMR. All project data was comprehensively checked, organized, and
de-identified at the end of the protocol implementation.
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Objective 5: Develop a plan of sustainability in the use of the systematic depression
screening protocol at the neurology clinic in South Florida.
To be sustained, the depression screening protocol required endorsement by practice
stakeholders and adoption as part of the routine patient examination process. Modifications were
made to the protocol to identify how often within a year the PHQ-9 should be administered to
each patient. Recommendations for the maintenance of staff, resident, and student training to
administer the PHQ-9 were also made. The lead neurologist remained responsible for validating
positive depression screens and making treatment recommendations as needed.
Recommendations were made to embed the PHQ-9 test into the EMR to facilitate future
sustainability. Embedding the PHQ-9 into the EMR would help make PHQ-9 administration,
results recording, and data management more efficient. Until then, the PHQ-9 would continue to
be administered by paper and scanned into the EMR. The approximate budget for in-house
printing was $.05 to $.10 per PHQ-9 test.
Objective 6: Disseminate the findings to the stakeholders.
Overall, the protocol implementation satisfied the project purpose of screening,
identifying, and recommending depression treatment to patients with neurological conditions.
For the purposes of the DNP evidence-based project, scores ranging from 5-27 (mild to severely
depressed) were considered positive for depression, and scores ranging from 0-4 (none to
minimal depression) were considered negative for depression. Table 6 is a summary of the DNP
practice change project findings.
The PHQ-9 and treatment recommendation results from the DNP evidence-based project
were disseminated to stakeholders. Demographic data from the patient sample population was
also shared with stakeholders. The clinician pre-and post-training test data was incomplete and
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unlinkable. As a result, there was no data from clinician pre- and post-training tests to report to
stakeholders.
Table 5
Evaluation of Objective and Outcome Data

Objective
Objective 1: Establish the
depression screening baseline
among the sample population.

Outcome
Documentation of the
systematic depression
screening baseline

Evaluation
Met: A needs assessment
demonstrated and
documented a systematic
depression screening baseline
of 0.

Objective 2: Develop an
evidence-based, systematic
depression screening protocol
at a neurology center in South
Florida.

Creation of a support-based
protocol that consists of
screening tool utilization,
clinician validation of tool
results, provision of treatment
if indicated, and provider
training on the overall
process (Siu & USPTF, 2016)

Met: A support-based,
systematic depression
screening protocol was
created that included
screening, clinician score
validation, and treatment
recommendations. Clinicians
were trained on PHQ-9
utilization and screening
protocol process.

Objective 3: Implement the
evidence-based depression
screening protocol.

Success of the practice
change protocol will be
measured by completion
counts of PHQ-9 screening in
the sample population as well
as provider pre- and posttests.

Met with limitations:
Incidences of screening,
screening scores, treatment
recommendations, and patient
demographics were
measured. Due to incomplete
data, clinician pre-training
and post-training data could
not be measured.

Objective 4: Evaluate the use
of the systematic depression
screening protocol through
weekly chart audit.

A spreadsheet will be used to
organize and reflect the
weekly counts of sample
population depression

Met: A spreadsheet was
created, documenting all
screening, treatment, and
demographic data. Provider
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screening as well as new
provider trainings and pretests or existing provider
posttests

pre-training and post-training
data was incomplete, though
collected and organized on
the spreadsheet.

Objective 5: Develop a plan
of sustainability in the use of
the systematic depression
screening protocol at the
neurology center in South
Florida.

The sustainability plan will
include an estimated annual
budget, equipment needed to
continue the program, EMR
updates or programming that
must be maintained, training
tools and a clear training
program, and provider buy-in

Met, ongoing: The
sustainability plan includes:
fiscal considerations, updates
for EMR integration, and
ideas for sustainable protocol
training and clinician
endorsement.

Objective 6: Disseminate the
findings to the stakeholders.

A program analysis including
counts of depression
screening, interventions,
comparative analytics of the
sample population scores and
demographics, statistical
analysis of the provider
training per the pre- and
posttest results as training
efficacy measure, budget
data, and unexpected findings
will be supplied to the
stakeholders.

Met, ongoing: Depression
and treatment incidences
were discussed with the
primary stakeholder as
protocol findings. Future
stakeholder meetings are
planned to further discuss
findings and sustainability
plans. Data from the provider
pre-training and post-training
tests were incomplete.

Note. Side-by-side list of each objective and corresponding expected outcome and evaluation
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Table 6
Summary of Positive Depression Screening and Treatment Counts
Positive for
Depression
(n = 37)

Positive for
Depression
(56.1%)

Received
Treatment
(n = 26)

Received
Treatment
(39.4%)

Category
Gender
Male
21
31.8
16
24.2
Female
16
24.2
10
15.2
Age
18-20
1
1.5
0
0
21-29
1
1.5
1
1.5
30-39
3
4.6
1
1.5
40-49
8
12.2
7
10.6
50-59
16
24.2
13
19.7
60+
8
12.2
6.1
Ethnicity
Non-Hispanic
11
16.7
8
12.12
Hispanic
17
25.7
14
21.2
Other
0
0
0
0
Not Indicated
9
13.7
4
6.1
Race
White
13
19.7
12
18.2
Black
7
10.6
5
7.5
Multiple
5
7.6
3
4.5
Other
6
9.1
3
4.5
Not Indicated
6
9.1
3
4.5
Diagnosis
Neurological
33
50
24
36.4
Comorbidities
Primary
3
4.5
1
1.5
Neurological
Diagnosis
Not Indicated
1
1.5
1
1.5
Note. Summary of positive depression screening and treatment results stratified by gender,
age, ethnicity, race, and neurological diagnosis

Table 6 summarizes the DNP practice change project results. Table 6 indicates that the
DNP practice change project successfully identified depression and recommended treatment to a
demographically diverse sample of patients with neurological conditions. Among the N = 66
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patient participants, 56.1% (n = 37) screened positive for depression, and 39.4% (n = 26)
received treatment recommendations. Depression screening and treatment recommendation
results of the practice change project were stratified by age, gender, ethnicity, race, and
neurological diagnosis.
Treatment options included none, re-evaluation at next visit, pharmaceutical intervention,
psychotherapeutic intervention, psychotherapeutic with pharmaceutical intervention, other, and
declined. Pharmaceutical intervention, 16.7% (n = 11), was the most common type of treatment
received by patient participants. Table 7 summarizes how many patients received each type of
treatment recommendation.
Table 7
Treatment Type Frequencies
Treatment Category
N = 66
%
Not indicated
39
59.1
Re-evaluate at next visit
1
1.5
Pharmaceutical intervention
11
16.7
Psychotherapeutic intervention
1
1.5
Pharmaceutical and psychotherapeutic intervention
4
6.1
Other
9
13.6
Declined
1
1.5
Note. Details number of patients who received each type of treatment recommendation

By age, people in their 50s, representing 24.2% (n = 16), represented the largest number
of patient participants who screened positive for depression. Thirteen of the patients in their 50s,
19.7%, received treatment. According to gender, 31.8% (n = 21) screened positive for depression
and received treatment more frequently than women. Sixteen women, 24.2% (n = 16) screened
positive for depression, and 15.2% (n = 10) received corresponding treatment recommendations.
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In Table 4, the four groups of Hispanic participants were combined under the title,
Hispanic. As shown in Table 3, Hispanic patients, 25.7% (n = 17), most commonly screened
positive for depression. Hispanic patients also more commonly received treatment
recommendations, 21.2% (n = 14) than any other individual ethnic group. Eleven, or 16.7%,
Non-Hispanic participants screened positive for depression, and 12.2% (n = 8) received
treatment recommendations. Figure 2 summarizes ethnicity and treatment results.
According to race, White participants, 19.7% (n = 13) most commonly screened positive
for depression. White participants, 18.2% (n = 12) also received the most treatment
recommendations. Figure 1 details race and treatment recommendations results.
Diagnostically, 24.2% (n = 50) patients with neurological comorbidities screened positive for
depression. Twenty-four participants with neurological comorbidities, or 36.5%, received
treatment recommendations.
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Figure 1. Summary of treatments administered to patients categorized by ethnicity.
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Figure 2. Summary of treatments administered to patients categorized by race.

Patients also self-reported the level of functional difficulty caused by the symptoms of
depression that they indicated on the PHQ-9. Most patients self-reported that the level of
functional difficulty resulting from their symptoms was either difficult or somewhat difficult,
31.8% (n = 21) in both categories. See Table 8 for details.
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Table 8
Levels of Functional Difficulty
Level of Difficulty

N = 66

%

Not difficulty

21

31.8

Somewhat difficult

21

31.8

Very difficult

12

18.2

Extremely difficult

2

3.0

Left blank

9

13.6

Multi select/other

1

1.5

Note. Patients self-reported levels of functional difficulty related to self-reported depression
symptoms on the PHQ-9.
Discussion
The DNP practice change project resulted in the successful implementation of a
depression screening protocol in a South Florida neurology clinic. Patients with neurological
conditions were screened, identified, and received treatment if indicated for depression. The
project answered the PICO question, demonstrating that the implementation of a systematic
depression screening protocol using the PHQ-9 screening tool did increase the screening,
identification, and treatment of depression in patients with neurological conditions in a South
Florida neurology clinic. The practice change project demonstrated that depression screening in
outpatient neurology is a possible means of meeting Siu and USPSTF (2016) national
recommendations for systematic, support-based screening of adults for depression.
Depression is a serious concern in patients with neurological conditions (Mayberg, 2016).
The DNP practice change project evidenced that the implementation of a support-based,
systematic depression screening protocol led to the identification of 56.1% (n = 37) and
treatment of 39.4% (n = 26) of patient participants. Prior to the practice change project, the
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baseline systematic screening, identification, and treatment of patients with depression was N =
0.
Strengths
Strengths of the DNP practice change project included the successful screening,
identification, and treatment of depression in patients with neurological conditions through the
use of a systematic depression screening protocol. Other strengths were the availability of
patients and clinicians for convenience sampling, supportive clinical leadership, interdisciplinary
collaboration, and immediate access to PHQ-9 data results. The PHQ-9 has also been
successfully used in other depression screening models, such as in the work of Loeb et al.
(2014). Other successful examples of depression screening and PHQ-9 utilization found in the
literature supportively validated the DNP practice change project. This validation was another
strength of the DNP practice change project, as well as the utilization of the EMR for data
recording, review, and analysis.
Limitations
Several limitations of the practice change project impacted the implementation and
outcomes of the protocol. The first was in regard to clinician training. The DNP student
conducted the clinician training with small groups or individuals. With each training, the DNP
student learned areas for improvement in organization, content, and delivery of the training. For
this reason, each training varied instead of sharing more precise consistency. Furthermore,
insufficient linkable clinician pre- and post-training test data made it impossible to provide
inferential data results on knowledge and attitude changes of clinician participants.
Another limitation was the small clinician participant sample size. The small number of
clinician participants made it unfeasible to simultaneously manage screening data and provide
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screening consultation to all participants. Due to the small number of clinician participants, the
DNP student disseminated and scored most of the screening exams. Obstacles to resident
participation included having to obtain affiliation agreements from certain residency programs
prior to residents participation in the DNP practice change project.
Literature suggests challenges in correctly and effectively treating depression in patients
(Mayberg, 2016). Due to time constraints and project design, the depression screening practice
change project provided only a single screening with treatment if indicated to each patient
participant. Future depression screening or treatment follow-up with each patient participant was
not a part of the screening protocol at the time. In the absence of follow-up, effectiveness of
treatment recommendations could not be evaluated. Future considerations included following up
with patients who were treated for depression to determine if they recovered from their
depression as a result of the treatment recommendations they received.
Recommendation for future implementation included that all patients who receive
treatment and those who score as moderately depressed or higher should receive a follow-up
phone call within a week of screening to ascertain that they are not having suicidal thoughts and
to ask if the patient has any questions about treatment. All patients who receive treatment
recommendations should be seen at a follow-up appointment within 2 months to assess how
effective the treatment has been for the patient. New treatment recommendations or adjustments
should be made at that time if indicated.
Participant inclusion in the protocol was limited to patients who were present at the clinic
for doctor appointments because the DNP practice change project was based on convenience
sampling. Due to the complexity of patients neurological diagnoses, inclusion criteria for
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participation included pre-screening patients for alertness and orientation to person, place,
month, and year.
Regarding PHQ-9 administration, depression severity may have been underreported on
tests where patients left specific answers blank. Paper PHQ-9 tests were also scanned and
charted into different parts of the EMR. Because all relevant protocol data results were not stored
or reported in the same place in the EMR, data abstraction from the EMR was moderately
challenging.
Managing the paper PHQ-9s and participant packet also posed challenges in that
sometimes the forms became separated from each other. Also, for approximately 15-20
consented patients, the slip of paper with the suicide hotline number was left out of the packet
accidentally. This error was disclosed to the IRB and corrective action of numbering each packet
and using a checklist to ensure complete packet contents was implemented. To rectify these
problems in the future, recommendations were that all pages of each packet should be numbered
with the same code. Furthermore, a checklist of each packet number and packet page should be
used to ensure that each packet contained all the required documents and that each patient
received all required documents.
Implications for Nursing Practice
The DNP practice change project effectively led to the identification and treatment of
depression in patients with neurological conditions. Contributions of the DNP practice change
project to the body of evidence regarding the utility of depression screening have healthcare,
population, and preventative health importance. The DNP practice change project also presented
valuable implications for nursing practice in regards to the DNP essentials.
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Scientific Underpinnings for Practice
DNP Essential I refers to the application of life sciences, health, and wholeness to the
advanced practice of the DNP graduate (American Association of Colleges of Nursing [AACN],
2006). A goal of the USPSTF is the preventative care of individuals not exhibiting overt signs of
illness (Siu & USPSTF, 2016). The DNP practice change project was informed by depression
screening recommendations of the USPSTF (2016) and its philosophy of screening to promote
health. From this standpoint of illness identification, depression screening addressed health and
wellness, incorporating an understanding of the life sciences and nursing practice as discussed in
DNP Essential I.
DNP Essential I also refers to the role of the nurse in impacting optimal health and
function for individuals (AACN, 2006). The PHQ-9 was created as a tool to aid in the diagnosis
and treatment of depression (Blackwell & McDermott, 2014). The PHQ-9 s design was based on
the itemized detection of nine diagnostic measurements of depression (Blackwell & McDermott,
2014). Through the utilization of the PHQ-9 screening tool, the DNP practice change project
demonstrated that symptoms of depression can be identified and treated as part of wellness
promotion and evidence-based practice.
Organizational and Systems Leadership
DNP Essential II states that organizational and systems leadership are integral to
healthcare improvement (AACN, 2006). National recommendations underscore that depression
screening and treatment programs should be systematic and support-based (Siu & USPSTF,
2016). The role of systems and organizational leadership in impacting change was underlined in
the development and implementation of this DNP practice change project. Effectively
establishing systematic depression screening in this DNP practice change project required
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sufficient time, staffing, and organizational support, emphasizing the role of organizational
leadership in advancing practice improvement. Organizational leadership in this practice change
project included project oversight from the DNP student as well as the commitment and
endorsement of the organization s operational management.
Clinical Scholarship and Analytic Methods
DNP Essential III discusses analytic problem solving and the scholarship of applying
knowledge to evidence-based practice in healthcare (AACN, 2006). A significant aspect of the
data collection and analysis process in the DNP practice change project was deciding what to
measure and analyze. For instance, when analyzing PHQ-9 descriptive statistics, occupation as a
demographic category was determined to be too varied to provide useful information in the
comparison of population demographics and PHQ-9 results. The value of clearly defining the
data collection parameters and the expected outcomes that will drive an organization s
depression screening protocol is a critical implication in clinical scholarship and analysis.
Information Systems
DNP Essential IV refers to the importance of proficient use of information technology in
healthcare quality improvement and data management (AACN, 2006). From implementation to
future considerations, information technology was instrumental in various aspects of the DNP
practice change project. Regarding implications for future considerations in depression
screening, embedding the PHQ-9 into the EMR would allow PHQ-9 screening results to be
saved directly into the EMR. Once saved directly into the EMR, PHQ-9 and treatment data could
be more easily accessed and analyzed for patient care and billing purposes. Depression screening
is a billable service both privately and through the Centers for Medicare and Medicaid Services
(CMS) (Savoy & O Gurek, 2016a). Though billing was not a part of the DNP practice change
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project, billing for depression could provide supportive reimbursement for protocol
sustainability.
Healthcare Policy for Advocacy in Healthcare
DNP Essential V addresses the responsibilities of the DNP nurse in regard to the many
aspects of healthcare policy and advocacy (AACN, 2006). In the DNP practice change project,
the DNP student played an insightful role in designing and directing the depression screening
protocol. The DNP student promoted depression screening as a policy change, thereby
advocating for patients who may have undiagnosed but treatable depression to be identified and
receive treatment. As aforementioned, depression is the preeminent cause of disability globally
(WHO, 2018). At worst, depression can result in death by suicide (WHO, 2018). The advocacy
implications of depression screening in outpatient neurology include the opportunity for
depression screening to be adopted as organizational policy so that all patients within a
neurology practice can have access to depression diagnosis, treatment, and suicide prevention if
needed.
Interprofessional Collaboration
According to DNP Essential VI, DNP graduates are equipped to effectively participate in
and lead interprofessional collaboration (AACN, 2006). Interprofessional collaboration was
essential to the execution and success of the DNP practice change project. The project included
administration of the PHQ-9 by participating clinicians, recording of the data by office
personnel, validation of PHQ-9 results and treatment recommendations by the lead neurologist,
and coordination by the nurse leader. Further, treatment included referrals for
neuropsychological evaluation and cognitive behavioral therapy. Therefore, the DNP practice
change project was an interprofessional, interdisciplinary, multi-professional collaborative effort.
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The implications of interprofessional collaboration from the DNP practice change project
included the leadership responsibility of the DNP student to invite and support the collaborative
participation of the interprofessional team.
Clinical Prevention and Population Health
DNP Essential VII defines and underscores the population health implications of
prevention interventions in promoting health for individuals, aggregates, and the nation (AACN,
2006). Nationally, Siu and the USPSTF (2016) recommended the systematic screening of all
U.S. adults for depression in a manner that provided adequate support for diagnosis, treatment,
and follow-up. The DNP practice change project demonstrated that systematic depression
screening led to the identification and treatment of adults with neurological conditions and
varying degrees of depression ranging from not depressed to severely depressed.
Advanced Nursing Practice
DNP Essential VIII focusses on the refined, specialized care, mentorship, and
professionalism exemplified by the DNP graduate (AACN, 2006). The DNP practice change
project required the DNP student to demonstrate high quality patient care, professionalism,
collaboration, and capacity building with the interprofessional team and oversight of the project.
Savoy and O Gurek (2016b) noted the difficulty in diagnosing depression, as it may be
confused with other comorbidities. The authors highlight how crucial correct diagnosis is for
appropriate treatment of depression (Savoy & O Gurek, 2016b). In the DNP practice change
project, the DNP student was instrumental in facilitating the processing of assessing and
screening patients with neurological conditions for depression. Nursing practice implications
evidenced in the DNP practice change project included the responsibility of the DNP student to
demonstrate expertise in patient assessment, leadership, technology and data management,
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interprofessional collaboration and training, and commitment to the health promotion and
advocacy importance of the screening protocol.
Conclusions
The DNP practice change project discussed in this manuscript led to the implementation
of a depression screening protocol that successfully identified and treated depression in
outpatients with neurological conditions at a neurology clinic in South Florida. The project
evidenced that systematic, support-based depression screening using the PHQ-9 effectively led to
the diagnosis of 56.1% (n = 37) and treatment of 39.4% (n = 26) participants of N = 66 patients
screened for depression. Implications of the project results in relation to the DNP essentials
included areas of preventive medicine, population health, patient advocacy, and organizational
policy. Other implications of the project and the DNP essentials included the reliance of protocol
success on advanced nursing practice, interprofessional collaboration, and teamwork. The results
of the DNP practice change project may contribute to the development of future evidence-based
practice in depression screening for outpatients with neurological conditions. Future research is
needed to determine the level of generalizability of the DNP practice change protocol results to
other neurology clinics and disciplines.
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Appendix C: Clinician Training Test

Depression Screening in Outpatient Neurology: Provider Pre-Training Survey
Favorite color: ________________ First 3 initials of your high school: ___ ___ ___
Demographic Information:
Resident:

Specialty: _________________________

Student:

Major:

Fellow:

Specialty: _________________________

Attending:

Specialty: _________________________

Gender: Male

Female

_________________________

Neutral

Part A
Instructions: Please read each question carefully and select the best response:
1. Which next-step action is best when patients self-test positive for suicidal ideation?
a. emergency intervention must be immediately provided and documented
b. the validating physician should further question the patient to confirm intention and
capability to carry out a suicide attempt
c. the patient should be scheduled for follow-up in two weeks for close monitoring
d. administer a suicide severity questionnaire to the patient
2. A severity score of 4 suggests what level of depression?
a. None
b. Moderate
c. Moderately severe
d. Severe
3. Which of the following is the proposed intervention for a severity score of 17?
a. None
b. Watchful waiting
c. Repeat the PHq-9 at the next follow-up
d. Active pharmacotherapy intervention
4. Which of the following is an appropriate intervention for a severity score of 27?
a. Watchful waiting
b. Repeat the PHQ-9 at the next follow-up
c. Active pharmacotherapy intervention
d. Immediate pharmacotherapy and expedited specialist referral
5. Which scenario may yield a PHQ-9 false positive?
a. The patient underwent a traumatic experience the week before PHQ-9 testing
b. The patient suffers from chronic illness
c. The patient speaks Spanish
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d. The screener knows the patient personally
Part B
Instructions: Please check the response that best fits your level of agreement with each
statement.
Strongly Disagree Neither Agree
Disagree
Disagree
Nor
Agree

Strongly
Agree

1. Screening for depression using a brief
self-report tool is a good idea
2. Screening neurology patients for
depression in the outpatient neurology
setting is beneficial to these patients
3. Depression is common enough to
warrant routine screening
4. I am confident in screening neurology
patients for depression
5. I am likely to screen neurology patients
for depression

*Adapted from the PND Attitudes and Screening Acceptability Questionnaire with permission
from Dr. Sarira El-Den (El-Den, O Reilly, & Chen, 2018).

75

Depression Screening in Outpatient Neurology: Provider Post-Training Survey
Favorite color:

First 3 initials of your high school:

Part A
Instructions: Please read each question carefully and select the best response:
1. Which next-step action is best when patients self-test positive for suicidal ideation?
a. emergency intervention must be immediately provided and documented
b. the validating physician should further question the patient to confirm intention and
capability to carry out a suicide attempt
c. the patient should be scheduled for follow-up in two weeks for close monitoring
d. administer a suicide severity questionnaire to the patient
2. A severity score of 4 suggests what level of depression?
a. None
b. Moderate
c. Moderately severe
d. Severe
3. Which of the following is the proposed intervention for a severity score of 17?
a. None
b. Watchful waiting
c. Repeat the PHq-9 at the next follow-up
d. Active pharmacotherapy intervention
4. Which of the following is an appropriate intervention for a severity score of 27?
a. Watchful waiting
b. Repeat the PHQ-9 at the next follow-up
c. Active pharmacotherapy intervention
d. Immediate pharmacotherapy and expedited specialist referral
5. Which scenario may yield a PHQ-9 false positive?
a. The patient underwent a traumatic experience the week before PHQ-9 testing
b. The patient suffers from chronic illness
c. The patient speaks Spanish
d. The screener knows the patient personally
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Part B
Instructions: Please check the response that best fits your level of agreement with each
statement.
Strongly
Disagree

Disagree

Neither
Disagree
Nor Agree

Agree

Strongly
Agree

1. Screening for depression using
a brief self-report tool is a good
idea
2. Screening neurology patients
for depression in the
outpatient neurology setting is
beneficial to these patients
3. Depression is common enough
to warrant routine screening
4. I am confident in screening
neurology patients for
depression
5. I am likely to screen neurology
patients for depression

*Adapted from the PND Attitudes and Screening Acceptability Questionnaire with permission
from Dr. Sarira El-Den (El-Den, O Reilly, & Chen, 2018).

Comments:
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
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Appendix D: English Demographic Questionnaire
Depression Screening in Outpatient Neurology Demographic Questionnaire
1. Which category below includes your age
o 18-20
o 21-29
o 30-39
o 40-49

o
o

50-59
60 or older

2. What is your race
o White
o Black
o American Indian or Alaskan Native

o
o
o

Native Hawaiian or Pacific Islander
Multiple Races
Other __________________

3. What is your ethnicity
o I am not Spanish, Hispanic, or Latino
o Mexican
o Mexican-American
o Chicano

o
o
o
o

Puerto Rican
Cuban
Cuban-American
Other Spanish, Hispanic, or Latino
Group
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Appendix E: Spanish Demographic Questionnaire
Evaluacion de la Depression en Pacientes Ambulatorios del Area de Neurologia
Demographic Questionnaire
4. En que categoria esta sue edad?
o 18-20
o 21-29
o 30-39
o 40-49

o
o

50-59
60 or older

5. Cual es tu raza?
o Blanco
o Negro
o Indio Americano o Nativo de Alaska.

o
o
o

Nativo de Hawaii o Isla del Pacifico
Razas multiples
Otro __________________

6. Cual es tu origan etnico/ de donde viniste
o No soy Hipano o Latino
o Mexicano
o Mexicano-Americano
o Chicano

o
o
o
o

Puerto Ricano
Cubano
Cubano-Americano
Other Espanol, Hispano
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Appendix F: NSU Consent to be in a Research Study Entitled
Depression Screening in Outpatient Neurology
Who is doing this research study?
This person doing this study is Lakicia Foster with the Department of Nursing at Nova
Southeastern University. She will be helped by Dr. Henson-Evertz (advisor) and Dr. Lori Lupe
(project chair).

Why are you asking me to be in this research study?
You are being asked to take part in this depression screening study because you are an adult
neurology patient.

Why is this research being done?
The purpose of this study is to screen all patients for depression according to national
recommendation that all adults be screened for depression in the U.S.

What will I be doing if I agree to be in this research study?
You will be taking a one-time, anonymous survey. The survey will take 5 minutes to complete.
The survey will be a part of your participation in a depression screening protocol at this site. You
will be consenting to participation in this screening process, receiving resulting intervention
recommendation from the provider, and giving permission for the publication of your
anonymous survey results as part of the study results.

Are there possible risks and discomforts to me?
This research study involves minimal risk to you. To the best of our knowledge, the things you
will be doing have no greater risk of harm than you would have in everyday life and doctor s
visit.

What happens if I do not want to be in this research study?
You can decide not to participate in this research at any time at no penalty or diminished care to
you. You can exit the survey at any time.
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Will it cost me anything? Will I get paid for being in the study?
There is no cost for participation in this study. Participation is voluntary and no payment will be
provided.

How will you keep my information private?
Your responses will be published with your consent. However, all published information will
remain anonymous. Information we learn about you in this research study will be handled in a
confidential manner, within the limits of the law and the HIPPA Privacy Rule. All data will be
secured in password protected files. This data will be available to the researcher, the Institutional
Review Board and other representatives of this institution, and any granting agencies (if
applicable). All confidential data will be electronically saved and kept securely password
protected, accessible only by medical staff overseeing your care and the project lead. All data
will be kept for 36 months from the end of the study and destroyed after that time by secure
deletion.
Who can I talk to about the study?
If you have questions, you can contact Lakicia Foster.
If you have questions about the study but want to talk to someone else who is not a part of the
study, you can call the Nova Southeastern University Institutional Review Board (IRB) at (954)
262-5369 or toll free at 1-866-499-0790 or email at IRB@nova.edu.
Do you understand and do you want to be in the study?
If you have read the above information and voluntarily wish to participate in this research study,
please complete the attached survey electronically or on paper.
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Adult Signature Section
Your signature documents your permission to take part in this research study.

Printed Name of Participant

Signature of Participant

Date

Printed Name of Witness

Signature of Witness

Date
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Appendix G: NSU IRB Short Form Consent to be in a Research Study
What is this form?
You are being asked to take part in a research study.
Before you agree to take part, someone will explain to you:

Why you are being asked to take part in research
The purposes of the research
How long you will be in the research
What will happen to you
What is experimental
Risks or discomforts to you
Benefits to you or others
Other choices you might have
Who will see your information
You volunteer to be in a research study
Whether or not you take part is up to you
You can choose not to take part.
You can agree to take part and later change your mind
Your decision will not be held against you
You can ask all the questions you want before you decide
Who can I talk to about the study?
If you have questions now, feel free to ask us. If you have additional questions, concerns,
comments or complaints later or you wish to report a problem, which may be related to this
study, please contact the research team with the information provided to you on the oral
summary sheet.
This research has been reviewed and approved by the Institutional Review Board (IRB) at Nova
Southeastern University, the committee that reviews research on human participants. You may
contact them at 954-262-5369 or irb@nova.edu. You may also visit NSU IRB website at
www.nova.edu/irb/information-for-research-participants for further information.

When applicable, someone will explain to you:
Whether you will get treated or paid if injured
The possibility of unknown risks
When you may be taken off the research without your agreement
Added costs from taking part
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What will happen if you stop taking part
Steps to safely stop taking part
When new information will be told to you
The number of people expected to take part
That the US Food and Drug Administration may inspect the records
What happens to collected data if you stop taking part
An explanation of www.ClinicalTrials.gov
Research Consent & Authorization Signature Section

Adult Signature Section
Your signature documents your permission to take part in this research study.

Printed Name of Participant

Signature of Participant

Date

Printed Name of Witness

Signature of Witness

Date
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Appendix H: The Patient Health Questionnaire
PATIENT HEALTH QUESTIONNAIRE-9 (PHQ-9)
Over the last 2 weeks, how often have you been
bothered by any of the following problems? Use ✔
to indicate your answer)

More
Several than half Nearly
Not at all days
the days every day

1. Little interest or pleasure in doing things

0

1

2

3

2. Feeling down, depressed, or hopeless

0

1

2

3

3. Trouble falling or staying asleep, or sleeping too much

0

1

2

3

4. Feeling tired or having little energy

0

1

2

3

5. Poor appetite or overeating

0

1

2

3

6. Feeling bad about yourself or that you are a failure
or have let yourself or your family down

0

1

2

3

7. Trouble concentrating on things, such as reading the
newspaper or watching television

0

1

2

3

8. Moving or speaking so slowly that other people
could have noticed? Or the opposite being so
fidgety or restless that you have been moving around a
lot more than usual

0

1

2

3

9. Thoughts that you would be better off dead or of
hurting yourself in some way

0

1

2

3

FOR OFFICE CODING
0

+ ______ + ______ + ______
=Total Score: ______
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If you checked off any problems, how difficult have these problems made it for you to
do your work, take care of things at home, or get along with other people?
Not difficult
at all
…

Somewhat
difficult
…

Very
difficult
…

Extremely
difficult
…

Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with
an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or
distribute.
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Appendix I: PHQ-9 (Spanish Version)

CUESTIONARIO SOBRE LA SALUD DEL
PACIENTE-9 (PHQ-9)
Durante las últimas 2 semanas, ¿qué tan seguido ha
tenido molestias debido a los siguientes problemas?
Marque con un
para indicar su respuesta

Más de
Casi
la mitad todos
de los
los días
días

Ningún
día

Varios
días

1. Poco interés o placer en hacer cosas

0

1

2

3

2. Se ha sentido decaído(a), deprimido(a) o sin esperanzas

0

1

2

3

3. Ha tenido dificultad para quedarse o permanecer
dormido(a), o ha dormido demasiado

0

1

2

3

4. Se ha sentido cansado(a) o con poca energía

0

1

2

3

5. Sin apetito o ha comido en exceso

0

1

2

3

6. Se ha sentido mal con usted mismo(a) – o que es un
fracaso o que ha quedado mal con usted mismo(a) o
con su familia

0

1

2

3

7. Ha tenido dificultad para concentrarse en ciertas
actividades, tales como leer el periódico o ver la
televisión

0

1

2

3

8. ¿Se ha movido o hablado tan lento que otras
personas podrían haberlo notado? o lo contrario –
muy inquieto(a) o agitado(a) que ha estado
moviéndose mucho más de lo normal

0

1

2

3

9. Pensamientos de que estaría mejor muerto(a) o de
lastimarse de alguna manera

0

1

2

3

FOR OFFICE CODING 0
=Total Score: ______

+ ______ + ______ + ______
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Si marcó cualquiera de los problemas, ¿qué tanta dificultad le han dado estos problemas
para hacer su trabajo, encargarse de las tareas del hogar, o llevarse bien con otras
personas?
No ha sido Un poco Muy Extremadamente difícil difícil difícil difícil

Elaborado por los doctores Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke y colegas,
mediante una subvención educativa otorgada por Pfizer Inc
. No se requiere permiso para
reproducir, traducir, presentar o distribuir.
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Appendix K: Letter of Permission to Use and Adapt Questionnaire

Dr Sarira El-Den
14/02/2019
To whom it may concern,
I, the undersigned, Dr Sarira El-Den, give permission to Lakicia Foster (Doctoral Candidate) to
use and adapt the PASAQ (instrument) for the purpose of her Doctoral Studies, only. Lakicia has
indicated that any doctoral research conducted using the PASAQ will clearly indicate the
changes/modifications made to the PASAQ and cite the original paper, authored by myself and
my colleagues:
El-Den S, O'Reilly CL, Chen TF. Development and Psychometric Evaluation of a
Questionnaire to Measure Attitudes Toward Perinatal Depression and Acceptability of
Screening: The PND Attitudes and Screening Acceptability Questionnaire (PASAQ).
Evaluation & the health professions 2018:163278718801434.
Please do not hesitate to contact me if I can provide any further information.
Kind regards,

Dr Sarira El-Den
Lecturer
The University of Sydney School of Pharmacy
Faculty of Medicine and Health
+61 2 8627 6417 | +61 438 016 905
sarira.el-den@sydney.edu.au

